Want to see JP:197A full AI Analyst Report?
Tauns Laboratories, Inc. (197A) Financial Statements
Tauns Laboratories, Inc. Financial Overview
Tauns Laboratories, Inc.'s market cap is currently $52.45B. The company's EPS TTM is $52.39; its P/E ratio is 9.37; and it has a dividend yield of 5.70%. Tauns Laboratories, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 14.37B | $ 18.63B | $ 18.43B | $ 15.67B | $ 17.46B |
| Gross Profit | $ 8.22B | $ 12.33B | $ 12.50B | $ 8.79B | $ 14.29B |
| Operating Income | $ 4.20B | $ 8.27B | $ 8.03B | $ 4.97B | $ 11.19B |
| EBITDA | $ 5.33B | $ 9.02B | $ 8.65B | $ 5.32B | $ 8.55B |
| Net Income | $ 5.50B | $ 6.32B | $ 5.77B | $ 3.03B | $ 4.48B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.56B | $ 9.27B | $ 9.42B | $ 1.24B | $ 6.35B |
| Total Assets | $ 44.62B | $ 36.52B | $ 29.26B | $ 18.81B | $ 20.88B |
| Total Debt | $ 21.26B | $ 14.42B | $ 9.54B | $ 6.47B | $ 4.90B |
| Net Debt | $ 17.70B | $ 5.16B | $ 114.11M | $ 5.22B | $ -1.45B |
| Total Liabilities | $ 25.20B | $ 19.10B | $ 15.59B | $ 10.32B | $ 13.52B |
| Stockholders' Equity | $ 19.42B | $ 17.42B | $ 13.67B | $ 8.49B | $ 7.36B |
| Cash Flow | |||||
| Free Cash Flow | $ -6.61B | $ 2.14B | $ 5.97B | $ -4.32B | $ 8.39B |
| Operating Cash Flow | $ -2.83B | $ 6.82B | $ 9.94B | $ -3.16B | $ 10.69B |
| Investing Cash Flow | $ -6.18B | $ -9.26B | $ -4.11B | $ -1.62B | $ -2.68B |
| Financing Cash Flow | $ 3.30B | $ 2.28B | $ 2.36B | $ -330.20M | $ -3.66B |
Currency in JPY